Arbutus Biopharma (ABUS) Expected to Announce Quarterly Earnings on Wednesday

Arbutus Biopharma (NASDAQ:ABUS) will likely be releasing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Arbutus Biopharma to post earnings of ($0.03) per share and revenue of $0.75 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 9:30 AM ET.

Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings data on Friday, March 20th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.05. The business had revenue of $1.05 million for the quarter, compared to the consensus estimate of $0.83 million. Arbutus Biopharma had a negative net margin of 237.88% and a negative return on equity of 42.39%.

Arbutus Biopharma Trading Up 0.1%

Shares of Arbutus Biopharma stock opened at $4.40 on Wednesday. The company’s fifty day simple moving average is $4.44 and its 200-day simple moving average is $4.43. The company has a market cap of $865.55 million, a price-to-earnings ratio of -25.85 and a beta of 0.62. Arbutus Biopharma has a 1 year low of $2.94 and a 1 year high of $5.10.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Arbutus Biopharma in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Arbutus Biopharma presently has an average rating of “Hold” and a consensus price target of $5.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley lifted its position in Arbutus Biopharma by 9.2% in the fourth quarter. Morgan Stanley now owns 26,702,776 shares of the biopharmaceutical company’s stock worth $128,440,000 after purchasing an additional 2,252,164 shares during the period. Two Seas Capital LP lifted its position in Arbutus Biopharma by 5.2% in the third quarter. Two Seas Capital LP now owns 10,991,261 shares of the biopharmaceutical company’s stock worth $49,900,000 after purchasing an additional 547,944 shares during the period. State Street Corp lifted its position in Arbutus Biopharma by 44.2% in the fourth quarter. State Street Corp now owns 5,908,211 shares of the biopharmaceutical company’s stock worth $28,418,000 after purchasing an additional 1,809,893 shares during the period. ADAR1 Capital Management LLC lifted its position in Arbutus Biopharma by 86.5% in the fourth quarter. ADAR1 Capital Management LLC now owns 5,415,109 shares of the biopharmaceutical company’s stock worth $26,047,000 after purchasing an additional 2,511,883 shares during the period. Finally, Geode Capital Management LLC lifted its position in Arbutus Biopharma by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 3,677,307 shares of the biopharmaceutical company’s stock worth $17,691,000 after purchasing an additional 11,145 shares during the period. 43.79% of the stock is owned by institutional investors.

About Arbutus Biopharma

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics.